TEPEZZA
(Teprotumumab)Phase 3Monoclonal antibody
TEPEZZA is a monoclonal antibody that works as a IGF-1R Inhibitor.[2] It is being investigated across 3 indications, with its most advanced program in Phase 3.[1]
TEPEZZA is one of 67 monoclonal antibody programs targeting Diabetic Macular Edema. It is currently in Phase 3.
3
Indications
13
Total Trials
3
Active Trials
66
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
180 competitors in Diabetic Macular Edema
#DrugCompanyPhaseTrials
1Eylea
RegeneronPhase 3
Lucentis
RochePhase 3
Avastin
BBio-Thera Solutions
Phase 3
Beovu
NovartisPhase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Synalar
EEurofarma Laboratorios S.A.
Phase 3
Lucentis
NovartisPhase 3
Luye Pharma Conbercept
CChengdu Kanghong Biotech Co., Ltd.
Phase 3
Glucophage
EMD SeronoPhase 3
Intravitreal Ranibizumab
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Thyroid Eye Disease8 trials
Show 5 more trials
Concentration1 trial
Ptosis1 trial
Diabetic Macular Edema1 trial
1 more indication
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Jan 21, 2020
TEPEZZA
BLA BLA761143
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Teprotumumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- IGF-1R Inhibitor[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- HHorizon Therapeutics Ireland DAC